Hansa Biopharma Receives Positive Reimbursement Decision for Idefirix (imlifidase) in the Czech Republic
- The reimbursement is received for desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor
- The 4 P-II efficacy and safety study of imlifidase was conducted as a pre-transplant treatment to reduce donor-specific IgG and plans to submit additional efficacy and safety data based on one observational follow-up study and one post-approval efficacy study
- Imlifidase, an enzyme derived from the bacterium Streptococcus pyogenes having ability to cleave with IgG and inactivate high levels of antibodies (anti-HLA) in highly sensitized patients to protect them from the binding to the donor organ and damage the transplant that increases the opportunity of transplantation
Ref: PR Newswire | Image: Hansa
Related News:- Hansa Biopharma's Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].